Pharma Marketing Network

JUNE 18, 2024

You must integrate and co-create from the outset, from clinical design to commercial execution to boost adherence, trial participation and create exceptional outcomes. YOU are the patient advocate in your company, so overturn tokenistic gestures into meaningful actions that prioritise patients over patents. This starts now.

Clinical Design 52

Clinical Design Trials Marketing 52

The Pharma Data

MARCH 20, 2021

“These focus areas will materialize in study designs as hybrid decentralized approaches that support global programs,” Reites said. “In In 2021, technology-enabled clinical research with a more global focus will become a standard clinical design approach.”. Source link: [link].

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

pharmaphorum

DECEMBER 21, 2020

Adding vaccination information, a self-service eligibility check, and booking functionality to Ask NHS lets patients, protect themselves and loved ones, quickly get the information they need and make appointments without having to call their clinic.

Nurses 75

Nurses Vaccination Vaccine Doctors 75

pharmaphorum

APRIL 6, 2021

Join over 28 world-class speakers to see how classic and next-gen tumor models can be leveraged to expand your mechanism of action understanding, model the complexities of the tumor microenvironment, and guide your clinical design. Download the full event guide here for more information on what you can look forward to.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

XTalks

JUNE 4, 2024

Cohen says this new infrastructure has been unveiled at Fortrea’s Leeds location in the UK and expanded to a couple of US clinics to include new Current Good Manufacturing Practice (CGMP) pharmacies. These changes, particularly the shift to fully digital spaces, facilitate more efficient and precise management of complex trials.

Clinical Development 95

Clinical Development Development Clinical Trials Clinical Trials 95

Advarra

JUNE 28, 2022

Using nonclinical data or manufacturing information that doesn’t adequately support the clinical protocol hurts the IND application. It’s critical to ensure all nonclinical data supports the clinical design and provides adequate justification of the desired labeling claims – including basic exposure data.

Regulation 52

Regulation Drugs Manufacturing Development 52